IM, an inhibitor of the tyrosine kinase activity of BCR-ABL, has been successfully used to treat CML patients in the CP and is considered the first-line therapy for the CP of CML (10–12). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.